Sep 21 2026 11:26 PM EST

PaySign Raises FY 2026 Revenue Guidance as Patient‑Affordability Business Accelerates

PaySign, Inc. (NASDAQ:PAYS) delivered Q2 2026 revenue of $28.25 million, up 48.1% YoY, and GAAP net income of $6.76 million. The results prompted management to raise its FY 2026 revenue outlook to $114‑$117 million, reinforcing a market re‑rating that has lifted the stock roughly 171% over the last six months.

Revenue growth was led by the patient‑affordability segment, which generated $14.6 million—an 88.9% increase YoY—while plasma‑related revenue rose 21.4% to $13.0 million. Adjusted EBITDA surged 113% to $9.61 million, and operating margin expanded to 24.8% (21.3% ex‑earn‑out). The company now carries zero bank debt and holds unrestricted cash of $27.4 million.

Guidance Raises the Stakes

Management lifted the FY 2026 revenue range to $114‑$117 million, a 39‑43% YoY increase, and adjusted EBITDA guidance to $35‑$38 million. Gross margin guidance was also upgraded to 62‑63% from the prior 60‑62% range. The revised outlook aligns with internal forecasts that patient‑affordability programs will continue to add roughly 50‑60 new contracts annually.

Patient‑Affordability Drives Margin Expansion

The pharma/copay‑assistance platform added 51 net programs in the twelve months to Q2 2026, bringing active programs to 148. Higher‑margin fees from program set‑up, per‑claim processing, and dynamic business‑rule services lifted gross profit to 63.3%, up 170 bps YoY. The segment now contributes a larger share of total revenue than the plasma business for the first time.

Plasma Segment Shows Utilization Gains

Plasma donor‑compensation revenue grew 21.4% YoY, supported by a monthly revenue per center of $7,699, the strongest level since Q3 2024. Although the center count slipped to 561, the higher per‑center revenue indicates improved utilization after inventory normalization.

Sector Tailwinds and Competitive Position

The prepaid‑card market is projected to grow at a 13.1% CAGR through 2030, while embedded‑finance services are expanding at nearly 20% YoY. PaySign’s vertically integrated platform—combining card issuance, processing, and donor‑management software—positions it to capture a share of the expanding digital‑payments ecosystem. Competitors lack an integrated solution that also addresses pharmaceutical copay assistance, creating a barrier to entry.

Valuation and Investor Sentiment

The stock trades around $12.63, giving a market cap of roughly $0.70 billion. Forward P/E is about 29.6×, versus a trailing P/E of 48.5×. Analyst consensus is “Strong Buy,” with average 12‑month price targets near $13‑$15. Recent insider sales have been described as routine and have not stemmed the share‑price rally.

Risks and Uncertainties

Key risks include the need to sustain the pipeline of new patient‑affordability programs; a slowdown in plasma‑center utilization could erode revenue; and tighter payment‑regulation could compress margins. The company also faces execution risk around the pending FDA review of its Apherion/BECS software platform, which could add a new revenue line but remains uncertain. Finally, the elevated Altman Z‑Score (1.46) signals a higher bankruptcy risk profile despite strong cash balances.